Market news

SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati

Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...

Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly m

Acadia hopes to become one of the first companies to secure approval for a therapy specifically indicated for ADP.

ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study […]

Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark.

Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo...

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its primary endpoint while meeting a key secondary measure at nominal statistical significance.

ACADIA Pharmaceuticals' (ACAD) shares dropped 10% pre-bell after it reported that its phase 2 RADIAN

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $33.85, a

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity. Thomas Garner, Acadia’s chief comme

Motley Fool Press Release.

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher ca

ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $33.50, a

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.